Efficacy and Safety of Solifenacin or Mirabegron With Local Estrogen Versus Combination Treatment With Mirabegron and Solifenacin for Refractory Overactive Bladder
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
To investigates the effects of solifenacin or mirabegron with local estrogen versus combination treatment with solifenacin and mirabegron in women with overactive bladder
Eligibility
Participation Requirements
Sex: Female
Minimum Age: 40
Maximum Age: 90
Healthy Volunteers: f
View:
• Patients with detrusor overactivity which defined as a urodynamic observation characterized by involuntary detrusor contractions during the filling phase. Those who were refractory to monotherapy with anti-muscarinics were enrolled for prospective study.
Locations
Other Locations
Taiwan
Mackay Memorial Hospital
RECRUITING
Taipei
Contact Information
Primary
Hui-Hsuan Lau, MD
huihsuan1220@gmail.com
+886-2-25433535
Time Frame
Start Date: 2022-06-16
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 300
Treatments
Active_comparator: Solifenacin and mirabegron
Solifenacin 5mg and Mirabegron 25mg
Experimental: Solifenacin with vaginal estrogen cream
Solifenacin 5mg once per day with vaginal conjugated equine estrogen (CEE) 0.625 mg twice a week.
Experimental: Mirabegron with vaginal estrogen cream
Mirabegron 25mg once per day with vaginal conjugated equine estrogen (CEE) 0.625 mg twice a week.
Related Therapeutic Areas
Sponsors
Leads: Mackay Memorial Hospital